Lidanserin
Lidanserin (International Nonproprietary Name, INN; ZK-33,839) is a drug which acts as a combined 5-HT2A receptor, 5-HT2A and α1-adrenergic receptor, α1-adrenergic receptor receptor antagonist, antagonist. It was developed as an antihypertensive agent but was never marketed. See also * Glemanserin * Pruvanserin * Roluperidone * Volinanserin * Lenperone * Iloperidone * Ketanserin References

5-HT2A antagonists Abandoned drugs Alpha-1 blockers Antihypertensive agents Ketones Fluoroarenes Piperidines Pyrrolidones {{nervous-system-drug-stub ...
[...More Info...]       [...Related Items...]     OR:     [Wikipedia]   [Google]   [Baidu]  

Glemanserin
Glemanserin (International Nonproprietary Name, INN) (developmental code name MDL-11,939) is a drug which acts as a potency (pharmacology), potent and binding selectivity, selective 5-HT2A receptor, 5-HT2A receptor receptor antagonist, antagonist. The first truly selective 5-HT2A ligand to be discovered, glemanserin resulted in the development of the widely used and even more potent and selective 5-HT2A receptor antagonist volinanserin (MDL-100,907), which is a fluorinated structural analog, analogue. Though it was largely superseded in scientific research by volinanserin, glemanserin was investigated clinical trial, clinically for the treatment of generalized anxiety disorder. However, it was ultimately found to be ineffective and was not marketed. See also * Volinanserin * Pruvanserin * Roluperidone * Lenperone * Lidanserin References

5-HT2A antagonists Secondary alcohols Phenol ethers Piperidines {{nervous-system-drug-stub ...
[...More Info...]       [...Related Items...]     OR:     [Wikipedia]   [Google]   [Baidu]